Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead

Boston Scientific’s stock sold off sharply due to EP and WATCHMAN slowdowns, but management/analyst commentary highlights that 74% of its portfolio is still growing healthily. The EP weakness is viewed as addressable via new launches (e.g., FARAWAVE Ultra and ICE), with recovery expected from 2H 2027 onward. Valuation also screens well at 15.27x forward earnings versus peers and historical averages, supporting a cautious but constructive setup.

Analysis

The market is likely treating BSX as if the underperformance in EP/WATCHMAN is a thesis break, when in reality it is more a mix issue: a high-growth core is still doing the heavy lifting, so the bear case is less about collapsing demand and more about delayed operating leverage. That distinction matters because a low-teens multiple on a diversified medtech platform is usually where the stock bottoms before fundamentals fully reaccelerate.

The catch is timing: the product cycle fix is a 2H27 story, so there is little in the next 1-3 quarters to force a rerating unless management can show stabilization in procedure growth, share, or adoption curves. In the interim, rivals with cleaner near-term narratives such as ABT in structural heart or broader quality medtech names may continue to command better relative ownership, while BSX absorbs the valuation penalty for being the "wait for the launch" name.

The contrarian risk is that the selloff may actually be too shallow if investors underestimate competitive leakage during the gap. If EP share loss is real rather than cyclical, then the 2027 launch cadence will only recover lost ground, not create upside, and the current discount is not obviously cheap enough for that uncertainty. Falsifier: another quarter of EP/WATCHMAN deceleration or any slip in the 2H27 launch timing would justify staying defensive; conversely, early evidence of stabilization would likely trigger fast multiple expansion off a depressed base.

Key Decisions for Investors

• Do not chase the stock immediately; wait for the next earnings/guidance update and require evidence that EP trends have stabilized before adding risk. This is a 6-18 month setup, not a 1-3 month catalyst trade.
• If you want exposure, use a long-dated bull call spread in BSX rather than common stock to express the 2H27 reacceleration optionality with limited theta burn. Structure it around a 12-18 month horizon and size modestly because the catalyst is far out.
• Relative value: long BSX / short MDT over 6-12 months if you want to own the lower-multiple medtech with a clearer self-help path and hedge out sector beta. The trade works if BSX merely stabilizes while MDT remains a slower-growth multiple anchor.
• Set a buy-alert on BSX if the forward multiple remains at or below ~15x while core revenue stays resilient; that is the zone where the market typically stops paying for perfection and starts paying for durability.
• Falsifier alert: if EP or WATCHMAN continues to decelerate into the next two reporting periods, reduce or exit any bullish exposure, since the stock may need another leg down before the 2027 launch story becomes investable.